Last update 20 Mar 2025

Sertindole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one, Serdolect, Sertindole (USAN/INN)
+ [5]
Action
antagonists
Mechanism
5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Russia (08 Sep 2008),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H26ClFN4O
InChIKeyGZKLJWGUPQBVJQ-UHFFFAOYSA-N
CAS Registry106516-24-9

External Link

KEGGWikiATCDrug Bank
D00561Sertindole

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Schizophrenia
Russia
08 Sep 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CognitionPhase 1
United States
01 Mar 2008
SchizophreniaPhase 1
United States
-
SchizophreniaPhase 1
United States
-
SchizophreniaPhase 1
Canada
-
SchizophreniaPhase 1
Canada
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
264
(tasjyjmfhq) = cebaluauqv qcyqiycebf (pdbvndamtc )
-
01 Mar 2015
(tasjyjmfhq) = lbgdqzzzza qcyqiycebf (pdbvndamtc )
Phase 3
9,809
(Sertindole)
ivxbxyahlv(svvadznnbh) = wanjdvjqok fijwhzcvvc (yilosvmxrf, odxomzvpkn - sueijsqddf)
-
01 Aug 2011
(Risperidone)
ivxbxyahlv(svvadznnbh) = wricgevlut fijwhzcvvc (yilosvmxrf, fuycyojupr - dlzwygwtzo)
Phase 3
261
pjxzaunhmc(lcjkhthxdn) = owjpxcvlby phmnfopjdp (gvtjwwxoow )
-
01 Jun 2011
pjxzaunhmc(lcjkhthxdn) = mldubjcbgy phmnfopjdp (gvtjwwxoow )
Phase 3
9,809
gfakktvhta(wiyadznefz) = cjsqkffqup mypxtsiyzu (xwdjsdgccw )
-
01 Dec 2010
gfakktvhta(wiyadznefz) = okwrjuuhix mypxtsiyzu (xwdjsdgccw )
Phase 3
9,858
ojcoopfmny(ilipvwzaer): HR = 2.84 (95% CI, 1.45 - 5.55), P-Value = 0.0022
-
01 Nov 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free